Monster changes label to qualify as 'drink' by FDA
WASHINGTON (AP) - One in four consumers found an error in a credit report issued by a major agency, according to a government study released Monday.
LOUISVILLE, Ky. (AP) - The producer of Maker's Mark bourbon is cutting - likely permanently - the amount of alcohol in each bottle to stretch every drop of the famous Kentucky whiskey. The alcohol volume is being lowered from its historic level of 45 percent to 42 percent - or 90 proof to 84 proof.
CHICAGO (AP) - Want to know how much a hip replacement will cost? Many hospitals won't be able to tell you, at least not right away - if at all. And if you shop around and find centers that can quote a price, the amounts could vary astronomically, a study found.
NEW YORK (AP) - If you don't like coffee or tea, Mountain Dew has a new breakfast drink that might perk you up.
SAN FRANCISCO (AP) - It can help overthrow dictators. But can it make money?
FREMONT (AP) - Tesla Motors' high-flying stock tumbled 12 percent in after-hours trading Tuesday after the electric car maker's third-quarter results fell short of expectations.
NEW YORK (AP) - SAC Capital Advisors will plead guilty to criminal fraud charges, stop investing money for others and pay $1.8 billion - the largest financial penalty in history for insider trading - to resolve criminal and civil claims against the hedge fund giant, the government announced Monday.
SAN FRANCISCO (AP) - San Francisco Mayor Ed Lee on Monday touted the city's plans to revitalize the long-neglected Mid-Market neighborhood by luring tech companies like Twitter, which is set to go public this week.
WASHINGTON (AP) - Johnson & Johnson has agreed to pay more than $2.2 billion to resolve criminal and civil allegations that the company promoted powerful psychiatric drugs for unapproved uses in children, seniors and disabled patients, the Department of Justice announced on Monday.
NEW YORK (AP) - Wal-Mart Stores Inc. is upping the ante on holiday shopping.
WASHINGTON (AP) - The Food and Drug Administration on Friday approved a new drug from Roche to help treat patients with a type of cancer of the blood and bone marrow. The agency cleared Gazyva to fight chronic lymphocytic leukemia in combination with chemotherapy in patients who haven't previously been treated for the disease. Gazyva works by killing cancer cells and encouraging the immune system to fight against them. Chronic lymphocytic leukemia develops slowly over ...